JPWO2021126929A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021126929A5
JPWO2021126929A5 JP2022537837A JP2022537837A JPWO2021126929A5 JP WO2021126929 A5 JPWO2021126929 A5 JP WO2021126929A5 JP 2022537837 A JP2022537837 A JP 2022537837A JP 2022537837 A JP2022537837 A JP 2022537837A JP WO2021126929 A5 JPWO2021126929 A5 JP WO2021126929A5
Authority
JP
Japan
Prior art keywords
polypeptide
amino acid
seq
interferon
homology
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022537837A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023514659A5 (https=
JP2023514659A (ja
JP7786010B2 (ja
Publication date
Priority claimed from ARP190103715A external-priority patent/AR117715A1/es
Application filed filed Critical
Publication of JP2023514659A publication Critical patent/JP2023514659A/ja
Publication of JPWO2021126929A5 publication Critical patent/JPWO2021126929A5/ja
Publication of JP2023514659A5 publication Critical patent/JP2023514659A5/ja
Application granted granted Critical
Publication of JP7786010B2 publication Critical patent/JP7786010B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022537837A 2019-12-17 2020-12-16 免疫原性が低下した修飾インターフェロン－アルファ－２ Active JP7786010B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AR20190103715 2019-12-17
ARP190103715A AR117715A1 (es) 2019-12-17 2019-12-17 Interferón hiperglicosilado con inmunogenicidad reducida
PCT/US2020/065246 WO2021126929A1 (en) 2019-12-17 2020-12-16 Modified interferon-alpha-2 having reduced immunogenicity

Publications (4)

Publication Number Publication Date
JP2023514659A JP2023514659A (ja) 2023-04-07
JPWO2021126929A5 true JPWO2021126929A5 (https=) 2023-12-25
JP2023514659A5 JP2023514659A5 (https=) 2023-12-25
JP7786010B2 JP7786010B2 (ja) 2025-12-16

Family

ID=76478524

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022537837A Active JP7786010B2 (ja) 2019-12-17 2020-12-16 免疫原性が低下した修飾インターフェロン－アルファ－２

Country Status (7)

Country Link
US (1) US20230127506A1 (https=)
EP (1) EP4076504A4 (https=)
JP (1) JP7786010B2 (https=)
AR (1) AR117715A1 (https=)
BR (1) BR112022011975A2 (https=)
MX (1) MX2022007546A (https=)
WO (1) WO2021126929A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024040247A1 (en) 2022-08-18 2024-02-22 Regeneron Pharmaceuticals, Inc. Interferon proproteins and uses thereof
US20240067691A1 (en) 2022-08-18 2024-02-29 Regeneron Pharmaceuticals, Inc. Interferon receptor agonists and uses thereof
AU2024274130A1 (en) 2023-05-12 2026-01-08 Regeneron Pharmaceuticals, Inc. Interferon receptor antagonists and uses thereof
CN116814595B (zh) * 2023-08-30 2023-11-28 江苏申基生物科技有限公司 一种腺苷脱氨酶突变体及其固定化

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
CA2439690A1 (en) 2001-03-02 2002-10-31 Merck Patent Gesellschaft Mit Beschraenkter Haftung Modified interferon alpha with reduced immunogenicity
CA2576030A1 (en) * 2004-08-09 2006-02-23 Alios Biopharma Inc. Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
WO2006133089A2 (en) 2005-06-03 2006-12-14 Ambrx, Inc. Improved human interferon molecules and their uses
EP1909822B1 (en) 2005-06-29 2013-09-25 Yeda Research And Development Co., Ltd. Recombinant interferon alpha 2 (ifn alpha 2) mutants
AR057215A1 (es) 2006-12-01 2007-11-21 Univ Nac Del Litoral Unl Proteina de fusion
US20080260820A1 (en) 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
MX2010001506A (es) 2007-08-06 2010-03-10 Schering Corp Moduladores de gamma secretasa.
CA2965414C (en) 2014-10-29 2024-01-09 Teva Pharmaceuticals Australia Pty Ltd Interferon .alpha.2.beta. variants
AR102120A1 (es) * 2015-09-29 2017-02-08 Univ Nac Del Litoral Interferón modificado con inmunogenicidad reducida
JP7534215B2 (ja) 2018-01-24 2024-08-14 ベイジン パーカンズ オンコロジー カンパニー リミテッド サイトカイン融合タンパク質

Similar Documents

Publication Publication Date Title
US20240254185A1 (en) Interleukin-2 variants and methods of uses thereof
AU2005256519B2 (en) Fc-interferon-beta fusion proteins
US5939286A (en) Hybrid interferon tau/alpha polypeptides, their recombinant production, and methods using them
JP2020120689A5 (https=)
US20020055492A1 (en) Monoclonal antibodies against the interferon receptor, with neutralizing activity against type 1 interferon
JP4637913B2 (ja) ヒトインターフェロンベータ変異体
JP2004536077A5 (https=)
US8273561B2 (en) High pressure treatment of aggregated interferons
JP7702445B2 (ja) 免疫調節融合タンパク質
CN111499718A (zh) 人α干扰素受体结合相关位点突变体及其用途
IL126835A (en) Interferon ALPHA / BETA receptor antibodies
JP2007535910A5 (https=)
RU2567007C1 (ru) Новый вариант альфа-1-антитрипсина, способ его получения и применения
BG64920B1 (bg) Комплекс ifnar2/ifn
JPWO2021126929A5 (https=)
BG108256A (bg) Интерферон-гама полипептидни разновидности
FI118084B (fi) Interferoni-alfa/beta-sitojaproteiini, sen valmistus ja käyttö
US7642072B2 (en) Optimized interferon-beta gene
JP2025516139A5 (https=)
JP2023522423A (ja) インターフェロンアルファ２バリアント及びその使用
Viscomi et al. Antigenic characterization of recombinant, lymphoblastoid, and leukocyte IFN-alpha by monoclonal antibodies
CN101883784B (zh) N-端修饰的干扰素-α
KR100464531B1 (ko) 잡종인터페론조성물및그것을사용하는방법
JPWO2020188081A5 (https=)
JPWO2022271466A5 (https=)